BEAM

SEC source: 0000899243-22-016164 · doc4.xml · derivative · entry 13

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,754

Underlying: Common Stock · 12,246 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 12

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 143,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.70 to $40.96, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 11

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 143,357

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.51 to $40.32, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 10

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 145,705

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.405 to $39.261, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 148,805

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.38 to $38.37, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 156,550

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $37.34, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118,520

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.08 to $40.80, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,119,620

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.21 to $39.88, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,124,123

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.09 to $38.67, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,130,965

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.06 to $37.86, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,144,620

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $36.97, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,148,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,101,316

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 11

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 0

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 10

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 3,200

F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $49.75 to $50.50. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 9

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 12,004

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.50 to $51.00. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 8

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 0

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 7

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 2,490,515

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 18,803

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 12,818

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 141,151

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 663

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 509,995

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001561 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 2,935,511

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000899243-22-013489 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,614

F2 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.

SEC source: 0000899243-22-013489 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,473

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.

SEC source: 0000899243-22-013487 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,089,070

F3 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.

SEC source: 0000899243-22-013487 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,095,331

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.

F2 · balance_after: Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022.

SEC source: 0000899243-22-013485 · doc4.xml · nonDerivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,278

F3 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.

SEC source: 0000899243-22-013485 · doc4.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,065

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.

F2 · balance_after: Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022.

SEC source: 0000899243-22-004196 · doc4.xml · derivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with Beam Therapeutics Inc. through each vesting date. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

SEC source: 0000899243-22-004198 · doc4.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000899243-22-004197 · doc4a.xml · derivative · entry 18

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2032-01-31

F16 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date.

SEC source: 0000899243-22-004197 · doc4a.xml · derivative · entry 17

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,345

Underlying: Common Stock · 100,000 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F15 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 15

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 163,000

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 14

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 165,672

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 13

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 175,080

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.00 to $66.94, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 12

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 179,185

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 11

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 181,085

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.17 to $64.50, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 10

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 182,700

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.26 to $63.58, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,038,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 938,825

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 942,803

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 956,338

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.09 to $66.94, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 962,675

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 965,852

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.21 to $64.50, inclusive.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 968,024

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.60 to $63.96, inclusive.

SEC source: 0000899243-21-050117 · doc4.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,702

Underlying: Common Stock · 39,700 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with Beam Therapeutics Inc. through such dates.

SEC source: 0000899243-21-050117 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-049634 · doc4.xml · derivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,646

Underlying: Common Stock · 2,607 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.